掌蹠膿疱症（PPP）- 市場考察、疫学、市場予測（2034年）

主なハイライト

• 主要7市場の掌蹠膿疱症（しょうせきのうほうしょう）の総市場規模は、2023年に約4億米ドルであり、予測期間（2024年～2034年）に成長が見込まれます。
• 欧州4ヶ国・英国では、2023年の掌蹠膿疱症の市場シェアはドイツが約60%でもっとも高く、フランス、英国がこれに続きます。これらの数字は予測期間（2024年～2034年）に増加する見込みです。
• 掌蹠膿疱症はあらゆる年齢層が罹患する可能性があり、男性よりも女性の方が罹患しやすいです。
• 2023年にPPPと診断された患者数は、日本がもっとも多いです。
• 米国では、40～64歳の年齢層でPPP患者数がもっとも多いです。
• 欧州4ヶ国・英国では、2023年に診断された患者数はドイツがもっとも多く、診断された患者数はスペインがもっとも少ないです。
• 主要7市場では、2023年に軽症患者が中等症患者を上回っています。
• PPPは、掌や足底に黄褐色の膿疱ができる疾患です。かつては乾癬に分類されており、現在では別の疾患となっていますが、PPP患者の10～25%は慢性尋常性乾癬も併発しています。
• 通常、医師は病歴聴取と皮膚の診察によってPPPを診断します。痛みのない皮膚の擦り傷で真菌感染の有無を調べ、膿疱液の綿棒で細菌感染を除外することができます。確認のために生検が必要なこともあります。
• 現在、PPPの治療法は確立されておらず、治療も困難で、米国でもEUでもPPPに特化した治療法は承認されていません。しかし、コルチコステロイド外用薬、光線療法、レチノイド内服薬、コールタール軟膏、皮膚保湿クリームなどの治療が症状の緩和に役立ちます。
• 現在、日本ではTREMFYA（Guselkumab）、LUMICEF（Brodalumab）、SKYRIZI（Risankizumab）の3剤がPPP治療薬として承認されています。
• OTEZLA（apremilast）はAmgenが開発中の薬剤で、PPPの治療薬としてフェーズIIIの開発段階にあります。
• 2024年9月、Amgenは、アムステルダムで開催されたEuropean Academy of Dermatology and Venereology（EADV）2024 Annual MeetingのLate-Breaking Research Sessionにおいて、日本人のPPP患者を対象にapremilastの有効性と安全性を評価したフェーズIII臨床試験の52週結果を発表しました。
• この疾患に苦しむ患者によりよい治療法を提供するために、疾患の理解と集中的な研究が必要とされています。

掌蹠膿疱症（PPP）市場の見通し

現在、掌蹠膿疱症に特化したFDA承認の薬剤はありませんが、複数の治療オプションに見込みがあります。局所治療は病変が限定的な患者には有効ですが、長期的な効果は持続しないことが多いです。生物学的製剤、JAK阻害薬、DMARDs、レチノイドなどの全身療法はPPPをクリアする可能性がありますが、副作用の可能性があります。光線療法も有効ですが、利用しやすさと費用に関する課題があります。

日本では現在、3種類の薬剤が掌蹠膿疱症（PPP）の治療薬として承認されています。2018年に承認されたIL-23 p19サブユニット阻害薬であるTREMFYA（Guselkumab）、2023年にPPPに対して初めて承認されたIL-17経路阻害薬であるLUMICEF（Brodalumab）、2023年5月にPPPに対して承認されたIL-23阻害薬であるSKYRIZI（Risankizumab）です。これらの治療薬は、重要な炎症性サイトカインを標的とし、既存の治療に反応しない患者のPPPを管理します。しかし、新規PPP治療薬のパイプラインはまだ限られており、AmgenのOTEZLA（apremilast）がもっとも注目すべき候補となっています。

一言で言えば、PPPを治療するために研究されている潜在的な治療法はそれほど多くありません。予測期間（2024年～2034年）に米国と欧州の市場に参入する上記の有望な候補についてコメントするのは時期尚早です。いずれにせよ、この薬剤は今後数年間でPPPの情勢に大きな変化をもたらすと見られます。この治療領域は、世界中で医療費の向上により、今後数年間で大きくプラスに転じると予測されます。

当レポートでは、掌蹠膿疱症（PPP）の主要7市場（米国、ドイツ、スペイン、イタリア、フランス、英国、日本）について調査分析し、各地域の市場規模、現在の治療法、アンメットニーズ、新薬などの情報を提供しています。

目次

第1章 重要考察

第2章 レポートのイントロダクション

第3章 PPP市場の概要

• 主要7市場のPPPの市場シェアの分布：国別（2023年）
• 主要7市場のPPPの市場シェアの分布：国別（2034年）

第4章 調査手法

第5章 エグゼクティブサマリー

第6章 重要な出来事

第7章 疾患の背景と概要

• 掌蹠膿疱症（PPP）
• 臨床症状と重症度の評価
• 組織学
• 危険因子
  • 喫煙
  • 感染症とストレス
  • 金属アレルギー
  • 誘発する薬剤
  • 併発疾患
• 生活の質と精神疾患
  • 遺伝的背景
• 病因
• 掌蹠膿疱症と掌蹠膿疱性乾癬（PPPP）の区別

第8章 PPPの治療と管理

• 局所治療
• 光線療法
• 全身治療
• 尋常性乾癬向けに承認された標的療法
  • TNF阻害薬
  • IL-12/23阻害薬
  • IL-23阻害薬
  • ホスホジエステラーゼ-4（PDE-4）阻害薬
• 新薬
  • IL8阻害薬
  • IL-36阻害薬
  • IL-1阻害薬
  • 顆粒球コロニー刺激因子受容体阻害薬

第9章 疫学と患者人口

• 主な調査結果
• 前提条件と根拠
• 主要7市場のPPPと診断された総患者数
• 主要7市場のPPPの治療された総患者数
• 米国
• 欧州4ヶ国・英国
• 日本

第10章 ペイシェントジャーニー

第11章 上市済みの治療法

• 主な競合
• TREMFYA（Guselkumab）：Janssen Pharmaceuticals/Taiho Pharmaceutical
  • 製品の説明
  • 規制のマイルストーン
  • その他の開発活動
  • 臨床開発
  • 安全性と有効性
• LUMICEF（Brodalumab）：Kyowa Kirin
• SKYRIZI（Risankizumab）：AbbVie/Boehringer Ingelheim

第12章 新治療法

第13章 掌蹠膿疱症（PPP）：主要7市場の分析

• 主な調査結果
• 市場見通し
• コンジョイント分析
• 主な市場予測の前提条件
• 主要7市場のPPPの総市場規模
• 米国の市場規模
  • 米国のPPPの総市場規模
  • 米国のPPPの市場規模：治療法別
• 欧州4ヶ国・英国の市場規模
  • 欧州4ヶ国・英国のPPPの総市場規模
  • 欧州4ヶ国・英国のPPPの市場規模：治療法別
• 日本の市場規模
  • 日本のPPPの総市場規模
  • PPPの市場規模：治療法別

第14章 KOLの見解

第15章 SWOT分析

第16章 アンメットニーズ

第17章 付録

第18章 DelveInsightのサービス内容

第19章 免責事項

List of Tables

• Table 1: Summary of PPP Market and Epidemiology (2020-2034)
• Table 2: Main Clinical Features of PPPP and PPP
• Table 3: Total Diagnosed Prevalent Cases of PPP in 7MM (2020-2034)
• Table 4: Total Treated Cases of PPP in 7MM (2020-2034)
• Table 5: Total Diagnosed Prevalent Cases of PPP in the United States (2020-2034)
• Table 6: Gender-specific Cases of PPP in the United States (2020-2034)
• Table 7: Age group-specific Cases of PPP in the United States (2020-2034)
• Table 8: Severity-specific Cases of PPP in the United States (2020-2034)
• Table 9: Total Treated Cases of PPP in the United States (2020-2034)
• Table 10: Total Diagnosed Prevalent Cases of PPP in EU4 and the UK (2020-2034)
• Table 11: Gender-specific cases of PPP in EU4 and the UK (2020-2034)
• Table 12: Age group-specific Cases of PPP in EU4 and the UK (2020-2034)
• Table 13: Severity-Specific Cases of PPP in EU4 and the UK (2020-2034)
• Table 14: Total Treated Cases of PPP in EU4 and the UK (2020-2034)
• Table 15: Total Diagnosed Prevalent Cases of PPP in Japan (2020-2034)
• Table 16: Gender-specific Cases of PPP in Japan (2020-2034)
• Table 17: Age group-specific Cases of PPP in Japan (2020-2034)
• Table 18: Severity-Specific Cases of PPP in Japan (2020-2034)
• Table 19: Total Treated Cases of PPP in Japan (2020-2034)
• Table 20: Key Cross of Marketed Therapies
• Table 21: TREMFYA (guselkumab), Clinical Trial Description, 2024
• Table 22: LUMICEF (brodalumab), Clinical Trial Description, 2024
• Table 23: SKYRIZI (Risankizumab), Clinical Trial Description, 2024
• Table 24: Key Cross of Emerging Therapies
• Table 25: OTEZLA (apremilast), Clinical Trial Description, 2024
• Table 26: Key Market Forecast Assumption of PPP in Japan
• Table 27: Total Market Size of PPP in the 7MM in USD Million (2020-2034)
• Table 28: Total Market Size of PPP in the United States in USD Million (2020-2034)
• Table 29: Market Size of PPP by Therapies in the United States in USD Million (2020-2034)
• Table 30: Total Market Size of PPP in EU4 and the UK in USD Million (2020-2034)
• Table 31: Market Size of PPP by Therapies in EU4 and the UK in USD Million (2020-2034)
• Table 32: Total Market Size of PPP in Japan in USD Million (2020-2034)
• Table 33: Market Size of PPP by Therapies in Japan in USD Million (2020-2034)

List of Figures

• Figure 1: Crops of Sterile Pustules on Both Soles
• Figure 2: Crops of Sterile Pustules on the Right Sole
• Figure 3: Typical Clinical Presentation
• Figure 4: Lesional Phases of PPP
• Figure 5: Risk Factors
• Figure 6: Hypothetical Model Showing the Effects of Cigarette Smoking in Patients With PPP
• Figure 7: Total Diagnosed Prevalent Cases of PPP in 7MM (2020-2034)
• Figure 8: Total Treated Cases of PPP in 7MM (2020-2034)
• Figure 9: Total Diagnosed Prevalent Cases of PPP in the United States (2020-2034)
• Figure 10: Gender-specific cases of PPP in the United States (2020-2034)
• Figure 11: Age group-specific Cases of PPP in the United States (2020-2034)
• Figure 12: Severity-specific Cases of PPP in the United States (2020-2034)
• Figure 13: Total Treated Cases of PPP in the United States (2020-2034)
• Figure 14: Total Diagnosed Prevalent Cases of PPP in EU4 and the UK (2020-2034)
• Figure 15: Gender-specific Cases of PPP in EU4 and the UK (2020-2034)
• Figure 16: Age group-specific Cases of PPP in EU4 and the UK (2020-2034)
• Figure 17: Severity-Specific Cases of PPP in EU4 and the UK (2020-2034)
• Figure 18: Total Treated Cases of PPP in EU4 and the UK (2020-2034)
• Figure 19: Total Diagnosed Prevalent Cases of PPP in Japan (2020-2034)
• Figure 20: Gender-specific cases of PPP in Japan (2020-2034)
• Figure 21: Age group-specific Cases of PPP in Japan (2020-2034)
• Figure 22: Severity-Specific Cases of PPP in Japan (2020-2034)
• Figure 23: Total Treated Cases of PPP in Japan (2020-2034)
• Figure 24: Total Market Size of PPP in the 7MM (2020-2034)
• Figure 25: Total Market Size of PPP in the US (2020-2034)
• Figure 26: Market Size of PPP by Therapies in the United States (2020-2034)
• Figure 27: Total Market Size of PPP in EU4 and the UK (2020-2034)
• Figure 28: Market Size of PPP by Therapies in EU4 and the UK (2020-2034)
• Figure 29: Total Market Size of PPP in Japan (2020-2034)
• Figure 30: Market Size of PPP by Therapies in Japan (2020-2034)
• Figure 31: Unmet Needs

Key Highlights:

• The total market size of Palmoplantar Pustulosis in 2023 was approximately USD 400 million in the 7MM, which is expected to grow during the forecast period (2024-2034).
• In the EU4 & the UK, Germany accounted for the highest Market share of Palmoplantar Pustulosis in 2023, with around 60% followed by France and the UK; these numbers are expected to increase during the forecast period (2024-2034).
• PPP can affect individuals of all ages, with females being more likely to be affected than males.
• In 2023, Japan accounted for the highest number of diagnosed prevalent cases of PPP.
• In the United States, individuals of the 40-64 year age group reported the highest number of PPP cases.
• In EU4 and the UK, Germany accounted for the highest number of diagnosed prevalent cases in 2023, while Spain accounted for the lowest number of diagnosed prevalent cases.
• In 7MM, Mild cases outnumbered moderate-severe cases in 2023.
• PPP is a condition with yellow-brown pustules on the palms and soles. Although once classified as psoriasis, it is now separate, though 10-25% of those with PPP also have chronic plaque psoriasis.
• A doctor usually diagnoses PPP by taking a history and examining the skin. A painless skin scrape can check for fungal infections, and a swab of pustule fluid may rule out bacterial infection. Sometimes, a biopsy is needed for confirmation.
• Currently, there is no cure for PPP and its treatment is challenging, with no approved treatments specifically for the disease in the US or EU. However, treatments like topical corticosteroids, phototherapy, oral retinoids, coal tar ointments, and skin-moisturizing creams can help alleviate symptoms.
• Currently, three drugs are approved specifically for the treatment of PPP in Japan, TREMFYA (Guselkumab), LUMICEF (Brodalumab), and SKYRIZI (Risankizumab).
• OTEZLA (apremilast), a drug that is being developed by Amgen, and is in Phase III development for treating PPP.
• In September 2024, Amgen presented 52-week results from a Phase III clinical trial evaluating the efficacy and safety of apremilast in Japanese patients with PPP during a Late-Breaking Research Session at the European Academy of Dermatology and Venereology (EADV) 2024 Annual Meeting in Amsterdam.
• There is a crucial need for understanding the disease and focused research for availing a better treatment to provide an ease to the patients suffering from the condition.

Report Summary

• The report offers extensive knowledge regarding the epidemiology segments and predictions, presenting a deep understanding of the potential future growth in diagnosis rates, disease progression, and treatment guidelines. It provides comprehensive insights into these aspects, enabling a thorough assessment of the subject matter.
• Additionally, an all-inclusive account of the current management techniques and emerging therapies and the elaborative profiles of late-stage (Phase III and Phase II) and prominent therapies that would impact the current treatment landscape and result in an overall market shift has been provided in the report.
• The report also encompasses a comprehensive analysis of the PPP market, providing an in-depth examination of its historical and projected market size (2020-2034). It also includes the market share of therapies, detailed assumptions, and the underlying rationale for our methodology. The report also includes drug outreach coverage in the 7MM region.
• The report includes qualitative insights that provide an edge while developing business strategies by understanding trends through SWOT analysis and expert insights/KOL views, including experts from various hospitals and prominent universities, patient journey, and treatment preferences that help shape and drive the 7MM PPP market.

Market

A few key players are leading the treatment landscape of PPP, such as Janssen, Kyowa Kirin, and others. The details of the country-wise and therapy-wise market size have been provided below.

• In 2023, Germany held the largest market share for PPP among the 7MM, with more than USD 120 million, followed by Japan with around USD 107 million.
• Among all the therapies available in the7MM, Biologics accounted for the highest market share with around USD 200 million in 2023.

Palmoplantar Pustulosis (PPP) Drug Chapters

The section dedicated to drugs in the PPP report provides an in-depth evaluation of late-stage pipeline drugs (Phase III and Phase II) related to PPP. The drug chapters section provides valuable information on various aspects related to clinical trials of PPP, such as the pharmacological mechanisms of the drugs involved, designations, approval status, patent information, and a comprehensive analysis of the pros and cons associated with each drug. Furthermore, it presents the most recent news updates and press releases on drugs targeting PPP.

Marketed Therapies

LUMICEF (brodalumab): Kyowa Kirin

Kyowa Kirin received approval from the Ministry of Health, Labour, and Welfare (MHLW) in Japan in August 2023, for a partial change in the approved indication of LUMICEF (brodalumab) to include the treatment of PPP in patients who have had an inadequate response to existing therapies. LUMICEF is a fully human anti-interleukin-17 (IL-17) receptor. An antibody that selectively inhibits inflammatory cytokines like IL-17A, IL-17A/F, IL-17F, and IL-17C by binding to the IL-17A receptor. This makes it the first IL-17 pathway inhibitor approved for PPP. The approval is based on positive results from a Phase III clinical trial in Japan, which showed that LUMICEF met its primary endpoint, confirming its efficacy and safety for PPP patients.

LUMICEF was first approved in Japan in 2016 for psoriasis and has since been approved for other indications, including ankylosing spondylitis. The approval of LUMICEF for PPP provides a new treatment option for patients suffering from this painful and debilitating condition.

SKYRIZI (risankizumab): AbbVie/ Boehringer Ingelheim

SKYRIZI (risankizumab) is a monoclonal antibody that works by binding to the p19 subunit of interleukin-23 (IL-23), a cytokine involved in the inflammatory process. By binding to this subunit, risankizumab effectively prevents IL-23 from interacting with its receptor on immune cells. This mechanism of action helps to reduce the inflammatory responses that are associated with certain autoimmune conditions, including PPP. By inhibiting the IL-23/IL-23 receptor interaction, risankizumab can modulate the immune system and reduce the overactive immune response that drives the symptoms of PPP. Currently, risankizumab is approved in Japan for the treatment of PPP, providing a targeted therapeutic option for patients with this chronic and challenging condition.

Emerging Therapies

OTEZLA (apremilast): Amgen

OTEZLA (apremilast) is an oral medication used to treat certain types of psoriasis and psoriatic arthritis. It works as a selective inhibitor of phosphodiesterase 4 (PDE4), which helps to reduce inflammation. In the United States, OTEZLA is approved for the treatment of adults with active psoriatic arthritis, plaque psoriasis in patients who are candidates for phototherapy or systemic therapy, and oral ulcers associated with Behcet's disease. In the European Union, OTEZLA is indicated for the treatment of active psoriatic arthritis in adults who have had an inadequate response to or have been intolerant of prior disease-modifying antirheumatic drug (DMARD) therapy. It is also approved for moderate to severe chronic plaque psoriasis in adults who have not responded to, are contraindicated for, or are intolerant of other systemic therapies such as cyclosporine, methotrexate, or psoralen and ultraviolet-A light.

Palmoplantar Pustulosis (PPP) Market Outlook

While no medications are currently FDA-approved specifically for PPP, several therapeutic options show promise. Topical treatments can be effective for patients with limited disease, though long-term responses are often not sustained. Systemic therapies, including biologics, JAK inhibitors, DMARDs, and retinoids, may achieve PPP clearance, but come with potential side effects. Phototherapy is also effective, though it can present challenges related to accessibility and cost.

In Japan, three drugs are currently approved for the treatment of Palmoplantar Pustulosis (PPP): TREMFYA (Guselkumab), an IL-23 p19 subunit inhibitor approved in 2018; LUMICEF (Brodalumab), the first IL-17 pathway inhibitor approved for PPP in 2023; and SKYRIZI (Risankizumab), an IL-23 inhibitor approved for PPP in May 2023. These therapies target key inflammatory cytokines to manage PPP in patients who do not respond to existing treatments. However, the pipeline for new PPP treatments remains limited, with OTEZLA (apremilast) by Amgen being the most notable candidate.

In a nutshell, not many potential therapies are being investigated to manage PPP. Even though it is too soon to comment on the above-mentioned promising candidate to enter the market of the US and Europe during the forecast period (2024-2034). Eventually, this drug will create a significant difference in the landscape of PPP in the coming years. The treatment space is expected to experience a significant positive shift in the coming years owing to the improvement in healthcare spending worldwide.

Palmoplantar Pustulosis (PPP) Disease Understanding and Treatment

Palmoplantar Pustulosis (PPP) Overview

PPP is a chronic skin condition characterized by the appearance of yellow-brown pustules on the palms of the hands and the soles of the feet. Once considered a type of psoriasis, PPP is now classified separately, though 10-25% of individuals with PPP may also have chronic plaque psoriasis. The exact cause of PPP is not fully understood, but contributing factors may include smoking, bacterial infections, contact allergies (especially to metals), and certain medications. Common symptoms of PPP include red, tender skin, blisters, pustules, itchiness, pain, and thick, scaly skin. While there is no cure for PPP, various treatments can help manage the symptoms and improve the quality of life for those affected.

Palmoplantar Pustulosis (PPP) Diagnosis

The diagnosis of PPP involves examining the affected skin and may include skin swabs to confirm the pustules are sterile, without bacteria or fungi. In some cases, a skin biopsy is needed, where a sample of the affected skin is taken and examined under a microscope to identify specific features of the disease. This helps differentiate PPP from other similar skin conditions, such as psoriasis. A thorough patient history, including potential triggers like smoking and infections, also aids in the diagnostic process.

Palmoplantar Pustulosis (PPP) Treatment

The main strategies for treating patients with PPP include topical agents, phototherapy, systemic therapies (such as acitretin and biologics), and emerging treatments targeting the IL-36 or IL-1 pathways. The treatment approach should be individualized, taking into account disease severity, patient preferences, and contraindications to certain therapies. These strategies aim to provide symptom relief and control inflammation while exploring new therapeutic targets such as monoclonal antibodies blocking IL-36.

Palmoplantar Pustulosis (PPP) Epidemiology

The PPP epidemiology chapter in the report provides historical as well as forecasted epidemiology segmented by total diagnosed prevalent cases, Gender-specific cases, Age-specific cases, Severity-specific cases, and total treated cases of PPP in the United States, EU4 countries (Germany, France, Italy, Spain) and the United Kingdom, and Japan from 2020 to 2034.

• In 2023, Japan accounted for the highest diagnosed prevalent cases of Palmoplantar Pustulosis with approximately 119,500 cases.
• In the United States, Females reported more cases than males with around 13,000 cases in 2023.

In 2023, the age group of 40-64 years accounted for the highest number of cases, with approximately 160,000 cases across the 7MM. This was followed by the 20-39 years age group, which had the second highest number of cases.

• In the United States, Mild cases outnumbered moderate-severe cases in 2023.

KOL Views

To stay abreast of the latest trends in the market, we conduct primary research by seeking the opinions of Key Opinion Leaders (KOLs) and Subject Matter Experts (SMEs) who work in the relevant field. This helps us fill any gaps in data and validate our secondary research.

We have reached out to industry experts to gather insights on various aspects of PPP, including the evolving treatment landscape, patients' reliance on conventional therapies, their acceptance of therapy switching, drug uptake, and challenges related to accessibility. The experts we contacted included medical/scientific writers, professors, and researchers from prestigious universities in the US, Europe, the UK, and Japan.

Our team of analysts at Delveinsight connected with more than 15 KOLs across the 7MM. We contacted institutions such as the Harvard Medical School, Skin Centre for Dermatology, GISED Study Center, etc., among others. By obtaining the opinions of these experts, we gained a better understanding of the current and emerging treatment patterns in the PPP market, which will assist our clients in analyzing the overall epidemiology and market scenario.

Qualitative Analysis

We perform Qualitative and Market Intelligence analysis using various approaches, such as SWOT analysis and Conjoint Analysis. In the SWOT analysis, strengths, weaknesses, opportunities, and threats in terms of disease diagnosis, patient awareness, patient burden, competitive landscape, cost-effectiveness, and geographical accessibility of therapies are provided. These pointers are based on the Analyst's discretion and assessment of the patient burden, cost analysis, and existing and evolving treatment landscape.

Conjoint Analysis analyzes multiple approved and emerging therapies based on relevant attributes such as safety, efficacy, frequency of administration, designation, route of administration, and order of entry. Scoring is given based on these parameters to analyze the effectiveness of therapy.

In efficacy, the trial's primary and secondary outcome measures are evaluated; for instance, in trials for PPP, One of the most important primary endpoints was achieving at least a 50% reduction from baseline in the PPP Area and Severity Index (PPPASI-50) at week 16. Based on these, the overall efficacy is evaluated.

Further, the therapies' safety is evaluated wherein the acceptability, tolerability, and adverse events are majorly observed, and it sets a clear understanding of the side effects posed by the drug in the trials. In addition, the scoring is also based on the route of administration, order of entry and designation, probability of success, and the addressable patient pool for each therapy. According to these parameters, the final weightage score and the ranking of the emerging therapies are decided.

Market Access and Reimbursement

Because newly authorized drugs are often expensive, some patients escape receiving proper treatment or use off-label, less expensive prescriptions. Reimbursement plays a critical role in how innovative treatments can enter the market. The cost of the medicine, compared to the benefit it provides to patients who are being treated, sometimes determines whether or not it will be reimbursed. Regulatory status, target population size, the setting of treatment, unmet needs, the number of incremental benefit claims, and prices can all affect market access and reimbursement possibilities.

The report further provides detailed insights on the country-wise accessibility and reimbursement scenarios, cost-effectiveness scenario of approved therapies, programs making accessibility easier and out-of-pocket costs more affordable, insights on patients insured under federal or state government prescription drug programs, etc.

Palmoplantar Pustulosis (PPP) Report Insights

• Patient Population
• Therapeutic Approaches
• PPP Market Size and Trends
• Existing Market Opportunity

Palmoplantar Pustulosis (PPP) Report Key Strengths

• Eleven-year Forecast
• The 7MM Coverage
• PPP Epidemiology Segmentation
• Key Cross Competition

Palmoplantar Pustulosis (PPP) Report Assessment

• Current Treatment Practices
• Reimbursements
• Market Attractiveness
• Qualitative Analysis (SWOT, Conjoint Analysis, Unmet needs)

Key Questions:

• Would there be any changes observed in the current treatment approach?
• Will there be any improvements in PPP management recommendations?
• Would research and development advances pave the way for future tests and therapies for PPP?
• Would the diagnostic testing space experience a significant impact and lead to a positive shift in the treatment landscape of PPP?
• What kind of uptake will the new therapies witness in the coming years in PPP patients?

Table of Contents

1. Key Insights

2. Report Introduction

3. PPP Market Overview at a Glance

• 3.1. Market Share (%) Distribution of PPP by Country in 2023 in the 7MM
• 3.2. Market Share (%) Distribution of PPP by Country in 2034 in the 7MM

4. Methodology

5. Executive Summary

6. Key Events

7. Disease Background and Overview

• 7.1. Palmoplantar Pustulosis (PPP)
• 7.2. Clinical Presentation and Severity Assessment
• 7.3. Histology
• 7.4. Risk Factors
  • 7.4.1. Smoking
  • 7.4.2. Infections and Stress
  • 7.4.3. Metal Allergy
  • 7.4.4. Triggering Drugs
  • 7.4.5. Concomitant Diseases
• 7.5. Quality of Life and Psychiatric Disorders
  • 7.5.1. Genetic Background
• 7.6. Pathogenesis
• 7.7. Differentiating Palmoplantar Pustulosis from Palmoplantar Pustular Psoriasis (PPPP)

8. Treatment and Management of PPP

• 8.1. Topical Treatment
• 8.2. Phototherapy
• 8.3. Systemic Treatment
• 8.4. Targeted Therapies Approved for Psoriasis Vulgaris
  • 8.4.1. TNF Inhibitors
  • 8.4.2. IL-12/23 Inhibitors
  • 8.4.3. IL-23 Inhibitors
  • 8.4.4. Phosphodiesterase-4 (PDE-4) Inhibitor
• 8.5. Emerging Agents
  • 8.5.1. IL 8 Inhibitors
  • 8.5.2. IL-36 Inhibitors
  • 8.5.3. IL-1 Inhibitors
  • 8.5.4. Granulocyte Colony Stimulating Factor Receptor Inhibitor

9. Epidemiology and Patient Population

• 9.1. Key Findings
• 9.2. Assumptions and Rationale
• 9.3. Total Diagnosed Prevalent Cases of PPP in 7MM
• 9.4. Total Treated Cases of PPP in 7MM
• 9.5. The United States
  • 9.5.1. Total Diagnosed Prevalent Cases of PPP in the United States
  • 9.5.2. Gender-specific Cases of PPP in the United States
  • 9.5.3. Age group-specific Cases of PPP in the United States
  • 9.5.4. Severity-specific Cases of PPP in the United States
  • 9.5.5. Treated Cases of PPP in the United States
• 9.6. EU4 and the UK
  • 9.6.1. Total Diagnosed Prevalent Cases of PPP in EU4 and the UK
  • 9.6.2. Gender-specific Cases of PPP in EU4 and the UK
  • 9.6.3. Age group-specific Cases of PPP in EU4 and the UK
  • 9.6.4. Severity-specific Cases of PPP in EU4 and the UK
  • 9.6.5. Total Treated Cases of PPP in EU4 and the UK
• 9.7. Japan
  • 9.7.1. Total Diagnosed Prevalent Cases of PPP Japan
  • 9.7.2. Gender-specific Cases of PPP in Japan
  • 9.7.3. Age group-specific Cases of PPP in Japan
  • 9.7.4. Severity-specific Cases of PPP in Japan
  • 9.7.5. Treated Cases of PPP in Japan

10. Patient Journey

11. Marketed Therapies

• 11.1. Key Cross Competition
• 11.2. TREMFYA (Guselkumab): Janssen Pharmaceuticals/Taiho Pharmaceutical
  • 11.2.1. Product Description
  • 11.2.2. Regulatory Milestones
  • 11.2.3. Other Developmental Activities
  • 11.2.4. Clinical Development
  • 11.2.5. Safety and Efficacy
• 11.3. LUMICEF (Brodalumab): Kyowa Kirin
  • 11.3.1. Product Description
  • 11.3.2. Regulatory Milestones
  • 11.3.3. Other Developmental Activities
  • 11.3.4. Clinical Development
  • 11.3.5. Safety and Efficacy
• 11.4. SKYRIZI (Risankizumab): AbbVie/Boehringer Ingelheim
  • 11.4.1. Product Description
  • 11.4.2. Regulatory Milestones
  • 11.4.3. Clinical Development
  • 11.4.4. Safety and Efficacy

12. Emerging Therapies

• 12.1. Key Cross Competition
• 12.2. OTEZLA (apremilast): Amgen
  • 12.2.1. Product Description
  • 12.2.2. Other Developmental Activities
  • 12.2.3. Clinical Developmental Activities
  • 12.2.4. Safety and Efficacy
  • 12.2.5. Analyst View

13. Palmoplantar Pustulosis (PPP): 7 Major Market Analysis

• 13.1. Key Findings
• 13.2. Market Outlook
• 13.3. Conjoint Analysis
• 13.4. Key Market Forecast Assumptions
• 13.5. Total Market Size of PPP in the 7MM
• 13.6. United States Market Size
  • 13.6.1. Total Market Size of PPP in the US
  • 13.6.2. Market Size of PPP by Therapies in the US
• 13.7. EU4 and the UK Market Size
  • 13.7.1. Total Market Size of PPP in EU4 and the UK
  • 13.7.2. Market Size of PPP by Therapies in EU4 and the UK
• 13.8. Japan Market Size
  • 13.8.1. Total Market Size of PPP in Japan
  • 13.8.2. Market Size of PPP by Therapies

14. KOL Views

15. SWOT Analysis

16. Unmet Needs

17. Appendix

• 17.1. Bibliography
• 17.2. Report Methodology

18. DelveInsight Capabilities

19. Disclaimer